Does Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox Interact with Valganciclovir?
CDI records a moderate classification for Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox and Valganciclovir. The stored summary is: Valganciclovir is eliminated by active tubular secretion; coadministration may increase concentrations of valganciclovir and emtricitabine/tenofovir, increasing risk of adverse reactions. The mechanism involves competition for active tubular secretion in kidneys. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox Class
- Cytochrome P450 3A Inhibitor
- Valganciclovir Class
- Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Competition for active tubular secretion in kidneys
What To Tell Your Doctor or Pharmacist
If you are taking Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox and your doctor is considering prescribing Valganciclovir (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider